Wall Street Weighs Impact On DYN Stock Post Novartis' Phase 3 Failure - RBC Says These Key Differences Could Lead To Better Outcomes

(MENAFN - AsiaNet News) RBC Capital cut its target to $30 from $35 while keeping an 'Outperform' rating, according to The Fly. Dyne is developing Z-Basivarsen for myotonic dystrophy type 1. On ...